ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of TALTZ® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs